Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects
Saved in:
| Title: | Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects |
|---|---|
| Authors: | Carina Lundby, Barbara Farrell, Amanda Wilson |
| Source: | British Journal of Clinical Pharmacology. 90:1741-1744 |
| Publisher Information: | Wiley, 2024. |
| Publication Year: | 2024 |
| Subject Terms: | geriatric medicine, Cognitive Dysfunction/chemically induced, elderly, Cholinergic Antagonists, Substance Withdrawal Syndrome, pharmacotherapy, 03 medical and health sciences, Deprescriptions, Cognition, 0302 clinical medicine, Substance Withdrawal Syndrome/drug therapy, antidepressants, Cognition/drug effects, Humans, Female, Cognitive Dysfunction, Cholinergic Antagonists/adverse effects, dementia, Aged |
| Description: | Anticholinergic‐induced cognitive impairment may be partially reversible upon cessation. A barrier to deprescribing of anticholinergics is the unknown risk of anticholinergic adverse drug withdrawal events (ADWE), with only limited information available on the incidence, timing and severity of anticholinergic ADWE. We report the case of a 76‐year‐old woman who experienced significant cognitive improvement following deprescribing long‐term use of a strong anticholinergic drug, doxepin, and dose reduction of another possible anticholinergic agent. The patient decided to abruptly stop taking doxepin, despite a planned careful taper with twice weekly monitoring, but did not experience any severe anticholinergic ADWE and subsequently had significantly improved cognitive function. Future research should focus on better understanding the risk of anticholinergic ADWE so that anticholinergic deprescribing decisions, including how often and by how much to taper, can be made confidently and safely. |
| Document Type: | Article |
| Language: | English |
| ISSN: | 1365-2125 0306-5251 |
| DOI: | 10.1111/bcp.16078 |
| Access URL: | https://pubmed.ncbi.nlm.nih.gov/38697619 |
| Rights: | CC BY NC ND |
| Accession Number: | edsair.doi.dedup.....0ac6591a52c1793c7b48ed77c3cd223d |
| Database: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Anticholinergic‐induced cognitive impairment may be partially reversible upon cessation. A barrier to deprescribing of anticholinergics is the unknown risk of anticholinergic adverse drug withdrawal events (ADWE), with only limited information available on the incidence, timing and severity of anticholinergic ADWE. We report the case of a 76‐year‐old woman who experienced significant cognitive improvement following deprescribing long‐term use of a strong anticholinergic drug, doxepin, and dose reduction of another possible anticholinergic agent. The patient decided to abruptly stop taking doxepin, despite a planned careful taper with twice weekly monitoring, but did not experience any severe anticholinergic ADWE and subsequently had significantly improved cognitive function. Future research should focus on better understanding the risk of anticholinergic ADWE so that anticholinergic deprescribing decisions, including how often and by how much to taper, can be made confidently and safely. |
|---|---|
| ISSN: | 13652125 03065251 |
| DOI: | 10.1111/bcp.16078 |